{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:18:38Z","timestamp":1781795918713,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.beem.2018.09.009","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T14:20:41Z","timestamp":1538144441000},"page":"837-845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Management of normocalcemic primary hyperparathyroidism"],"prefix":"10.1016","volume":"32","author":[{"given":"Natalie E.","family":"Cusano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.beem.2018.09.009_bib1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1172\/JCI100349","article-title":"Studies of calcium and phosphorus metabolism: XVIII. On temporary fluctuations in the level of calcium and inorganic phosphorus in blood serum of normal individuals","volume":"10","author":"Farquharson","year":"1931","journal-title":"J\u00a0Clin Invest"},{"issue":"8","key":"10.1016\/j.beem.2018.09.009_bib2","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1210\/jc.2006-2802","article-title":"Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype","volume":"92","author":"Lowe","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"10","key":"10.1016\/j.beem.2018.09.009_bib3","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1210\/jc.2002-021404","article-title":"Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone","volume":"88","author":"Maruani","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"10","key":"10.1016\/j.beem.2018.09.009_bib4","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1210\/jc.2014-1414","article-title":"Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth international Workshop","volume":"99","author":"Eastell","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.009_bib5","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/0002-9343(69)90222-8","article-title":"Normocalcemic primary hyperparathyroidism","volume":"47","author":"Wills","year":"1969","journal-title":"Am J Med"},{"key":"10.1016\/j.beem.2018.09.009_bib6","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.surg.2004.06.052","article-title":"Normocalcemic hyperparathyroidism in patients with osteoporosis","volume":"136","author":"Monchik","year":"2004","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.beem.2018.09.009_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jocd.2012.12.001","article-title":"Normocalcemic primary hyperparathyroidism","volume":"16","author":"Cusano","year":"2013","journal-title":"J\u00a0Clin Densitom"},{"issue":"2","key":"10.1016\/j.beem.2018.09.009_bib7A","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1530\/EJE-13-0102","article-title":"Prevalence of subclinical contributors to low bone mineral density and\/or fragility fracture","volume":"169","author":"Eller-Vainicher","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2018.09.009_bib8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0272-6386(97)90330-9","article-title":"The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure","volume":"29","author":"Martinez","year":"1997","journal-title":"Am J Kidney Diss"},{"key":"10.1016\/j.beem.2018.09.009_bib9","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","year":"2009","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"10.1016\/j.beem.2018.09.009_bib10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1365-2796.2001.00868.x","article-title":"Effects of thiazide-and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study","volume":"250","author":"Rejnmark","year":"2001","journal-title":"J\u00a0Intern Med"},{"issue":"2","key":"10.1016\/j.beem.2018.09.009_bib11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2796.2004.01434.x","article-title":"Effects of long-term treatment with loop diuretics on bone mineral density, calcitropic hormones and bone turnover","volume":"257","author":"Rejnmark","year":"2005","journal-title":"J\u00a0Intern Med"},{"issue":"2","key":"10.1016\/j.beem.2018.09.009_bib12","doi-asserted-by":"crossref","first-page":"L27","DOI":"10.1210\/jc.2014-4065","article-title":"Letter to the editor: thiazides are not inducers of PTH secretion: a comment on normocalcemic hyperparathyroidism","volume":"100","author":"Yacobi-Bach","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"3","key":"10.1016\/j.beem.2018.09.009_bib13","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1210\/jc.2015-3964","article-title":"Thiazide-associated hypercalcemia: incidence and association with primary hyperparathyroidism over two decades","volume":"101","author":"Griebeler","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.beem.2018.09.009_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1600-0447.1995.tb09741.x","article-title":"Renal, thyroid and parathyroid function during lithium treatment: laboratory tests in 207 people treated for 1\u201330 years","volume":"91","author":"Kallner","year":"1995","journal-title":"Acta Psychiatr Scand"},{"issue":"9","key":"10.1016\/j.beem.2018.09.009_bib15","first-page":"2844","article-title":"Alterations in parathyroid dynamics in lithium-treated subjects","volume":"82","author":"Haden","year":"1997","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"2","key":"10.1016\/j.beem.2018.09.009_bib16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.beem.2018.09.009_bib17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.beem.2018.09.009_bib18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/cen.12188","article-title":"Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis","volume":"79","author":"Makras","year":"2013","journal-title":"Clin Endocrinol"},{"issue":"10","key":"10.1016\/j.beem.2018.09.009_bib19","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1111\/bcp.13332","article-title":"Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a pilot study","volume":"83","author":"Cipriani","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.beem.2018.09.009_bib20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1172\/JCI107156","article-title":"Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria","volume":"52","author":"Coe","year":"1973","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.beem.2018.09.009_bib21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.semnephrol.2008.01.005","article-title":"New insights into the pathogenesis of idiopathic hypercalciuria","volume":"28","author":"Worcester","year":"2008","journal-title":"Semin Nephrol"},{"issue":"7","key":"10.1016\/j.beem.2018.09.009_bib21A","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1210\/jc.2014-4548","article-title":"Hypercalciuria may persist after successful parathyroid surgery and it is associated with parathyroid hyperplasia","volume":"100","author":"Palmieri","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"4","key":"10.1016\/j.beem.2018.09.009_bib22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1210\/er.2001-0035","article-title":"Endocrinological disorders and celiac disease","volume":"23","author":"Collin","year":"2002","journal-title":"Endocr Rev"},{"issue":"7","key":"10.1016\/j.beem.2018.09.009_bib23","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1210\/jc.2013-1300","article-title":"Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations","volume":"98","author":"Cusano","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"3","key":"10.1016\/j.beem.2018.09.009_bib24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1530\/EC-15-0030","article-title":"Normocalcemic primary hyperparathyroidism: a survey in a small village of Southern Italy","volume":"4","author":"Vignali","year":"2015","journal-title":"Endocrine Connections"},{"issue":"3","key":"10.1016\/j.beem.2018.09.009_bib25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0039-6060(97)90357-3","article-title":"Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women","volume":"121","author":"Lundgren","year":"1997","journal-title":"Surgery"},{"key":"10.1016\/j.beem.2018.09.009_bib26","first-page":"1","article-title":"Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women","author":"Garc\u00eda-Mart\u00edn","year":"2012","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.beem.2018.09.009_bib27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1590\/S0004-27302011000500003","article-title":"Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat?","volume":"55","author":"Marques","year":"2011","journal-title":"Arquivos Brasileiros Endocrinol Metabol"},{"issue":"11","key":"10.1016\/j.beem.2018.09.009_bib28","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.amjmed.2004.06.037","article-title":"Characterization of normocalcemic primary hyperparathyroidism","volume":"117","author":"Tordjman","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.beem.2018.09.009_bib29","first-page":"128352","article-title":"Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone?","volume":"2012","author":"Amaral","year":"2012","journal-title":"J\u00a0Osteoporos"},{"issue":"2","key":"10.1016\/j.beem.2018.09.009_bib30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12020-012-9627-x","article-title":"Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism","volume":"42","author":"Cakir","year":"2012","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.beem.2018.09.009_bib31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00268-012-1438-y","article-title":"Surgical management of normocalcemic primary hyperparathyroidism","volume":"36","author":"Wade","year":"2012","journal-title":"World J Surg"},{"issue":"3","key":"10.1016\/j.beem.2018.09.009_bib32","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4158\/EP15704.OR","article-title":"Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat?","volume":"22","author":"\u0160iprov\u00e1","year":"2016","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.beem.2018.09.009_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02173","article-title":"Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening","volume":"155","author":"Hagstr\u00f6m","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2018.09.009_bib34","first-page":"1","article-title":"Normocalcemic hyperparathyroidism and insulin resistance","author":"Temizkan","year":"2014","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.beem.2018.09.009_bib35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1507\/endocrj.EJ15-0392","article-title":"Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients","volume":"63","author":"Yener Ozturk","year":"2016","journal-title":"Endocr J"},{"issue":"6","key":"10.1016\/j.beem.2018.09.009_bib36","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1210\/jc.2014-4432","article-title":"Is normocalcemic primary hyperparathyroidism harmful or harmless?","volume":"100","author":"Chen","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"5","key":"10.1016\/j.beem.2018.09.009_bib37","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1530\/EJE-09-1067","article-title":"Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism","volume":"162","author":"Tordjman","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2018.09.009_bib38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/VHRM.S128084","article-title":"Evaluation of coronary calcium score in patients with normocalcemic primary hyperparathyroidism","volume":"13","author":"Mesquita","year":"2017","journal-title":"Vasc Health Risk Manag"},{"issue":"10","key":"10.1016\/j.beem.2018.09.009_bib39","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1210\/jc.2014-1413","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop","volume":"99","author":"Bilezikian","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"7","key":"10.1016\/j.beem.2018.09.009_bib40","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1210\/jc.2003-030908","article-title":"Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial","volume":"89","author":"Khan","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"7","key":"10.1016\/j.beem.2018.09.009_bib41","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4158\/EP08178.ORR","article-title":"Alendronate therapy in men with primary hyperparathyroidism","volume":"15","author":"Khan","year":"2009","journal-title":"Endocr Pract"},{"key":"10.1016\/j.beem.2018.09.009_bib42","first-page":"1","article-title":"Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism","author":"Cesareo","year":"2014","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.beem.2018.09.009_bib43","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4081\/aiua.2015.1.66","article-title":"Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study","volume":"87","author":"Brardi","year":"2015","journal-title":"Archivio Italiano di Urologia e Andrologia"},{"key":"10.1016\/j.beem.2018.09.009_bib44","doi-asserted-by":"crossref","DOI":"10.1111\/1754-9485.12728","article-title":"Better performance of four-dimension computed tomography as a localization procedure in normocalcemic primary hyperparathyroidism","author":"Cunha-Bezerra","year":"2018","journal-title":"J\u00a0Med Imag Radiat Oncol"},{"issue":"3","key":"10.1016\/j.beem.2018.09.009_bib45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00423-018-1659-0","article-title":"Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism?","volume":"403","author":"Traini","year":"2018","journal-title":"Langenbeck's Arch Surg"},{"issue":"4","key":"10.1016\/j.beem.2018.09.009_bib46","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00268-018-4512-2","article-title":"Classic primary hyperparathyroidism versus normocalcemic and normohormonal variants: do they really differ?","volume":"42","author":"Kiriakopoulos","year":"2018","journal-title":"World J Surg"},{"issue":"1","key":"10.1016\/j.beem.2018.09.009_bib47","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.surg.2016.08.054","article-title":"Differences in single gland and multigland disease are seen in low biochemical profile primary hyperparathyroidism","volume":"161","author":"Lim","year":"2017","journal-title":"Surgery"},{"issue":"8","key":"10.1016\/j.beem.2018.09.009_bib48","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1210\/jc.2013-1518","article-title":"Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism","volume":"98","author":"Koumakis","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"7","key":"10.1016\/j.beem.2018.09.009_bib49","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1007\/s00198-014-2689-2","article-title":"Individual site-specific bone mineral density gain in normocalcemic primary hyperparathyroidism","volume":"25","author":"Koumakis","year":"2014","journal-title":"Osteoporos Int"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X1830109X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X1830109X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:55:15Z","timestamp":1761497715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X1830109X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1521690X1830109X"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2018.09.009","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of normocalcemic primary hyperparathyroidism","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2018.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}